Article

Immunogenicity and safety of DS-5670d, an mRNA-based COVID-19 vaccine targeting omicron XBB.1.5: Results from a phase 3, randomized, active-controlled study in adults and children aged ≥12 years

2024-11-15

Abstract excerpt

<h4>Background</h4> Many people worldwide have now acquired immune responses against the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) following previous vaccination and/or infection. As a result, national vaccination programs are now implementing a simplified schedule of single-dose administration and seasonal boosters. In this phase 3 non-inferiority study, we assessed the immunogenicity and safet...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 117d161c-25c4-597a-83a1-986994e44b29
DOI: 10.1101/2024.11.14.24317321

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity and safety of DS-5670d, an mRNA-based COVID-19 vaccine targeting omicron XBB.1.5: Results from a phase 3, randomized, active-controlled study in adults and children aged ≥12 yearsDOI 10.1101/2024.11.14.24317321Read

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim ReportSemantic proximity Read

Safety and Immunogenicity of XBB.1.5-Containing mRNA VaccinesSemantic proximity Read

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 VaccineSemantic proximity Read

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity Read

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity Read

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trialSemantic proximity Read

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read

Elasomeran (mRNA1273) Vaccine: The Journey from Preclinical Research to Clinical Trials, Authorization, and FDA ApprovalSemantic proximity Read

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE FrameworkSemantic proximity Read

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humansSemantic proximity Read

Concurrent human antibody and T<sub>H</sub>1 type T-cell responses elicited by a COVID-19 RNA vaccineSemantic proximity Read

A Bivalent Omicron-containing Booster Vaccine Against Covid-19Semantic proximity Read